Adoptive cell therapy, the use of immune cells to help fight disease, is seeing rapid growth in the oncology industry, with indications now spanning hematological and solid malignancies. From September 5th-6th, 2024, the Alliance for Regenerative Medicine (ARM) held a 1.5-day workshop on cell-based immuno-oncology (IO) to explore the current and future state of autologous and allogeneic cellular immunotherapies for treating cancer. The workshop brought together academic experts, therapeutic developers, regulatory representatives, and other key stakeholders from across the industry.
The goals of the workshop were to (1) share clinical program updates, success stories, and key advances in manufacturing; (2) discuss how to resolve barriers to patient access for commercial products; (3) review novel next-generation T cell-based and innate approaches to IO development; and (4) discuss new and upcoming regulatory guidance documents and their applicability to cell-based–IO development. The importance of patient centricity emerged across topics and is discussed throughout the whitepaper.
The full whitepaper is free for ARM members to access on our community portal. If you are not an ARM member, but would like to view the full document, you can purchase full access to the whitepaper here.
Full Whitepaper – Members Only Access
